Literature DB >> 22608987

The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.

Peter R Kowey, Gerald V Naccarelli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608987     DOI: 10.1016/j.amjmed.2011.10.035

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  4 in total

1.  New oral anticoagulants: discussion on monitoring and adherence should start now!

Authors:  Hugo Ten Cate
Journal:  Thromb J       Date:  2013-06-28

2.  Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.

Authors:  Luigi Brunetti; Betty Sanchez-Catanese; Leonid Kagan; Xia Wen; Min Liu; Brian Buckley; James P Luyendyk; Lauren M Aleksunes
Journal:  Thromb J       Date:  2016-05-06

3.  Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?

Authors:  Jun R Chiong; Rebecca J Cheung
Journal:  Korean Circ J       Date:  2013-05       Impact factor: 3.243

4.  Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Authors:  Benjamin A Steinberg; Dajuanicia N Holmes; Jonathan P Piccini; Jack Ansell; Paul Chang; Gregg C Fonarow; Bernard Gersh; Kenneth W Mahaffey; Peter R Kowey; Michael D Ezekowitz; Daniel E Singer; Laine Thomas; Eric D Peterson; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2013-11-25       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.